Devonian Health Group enhances quality control for Thykamine™
QUEBEC, Sept. 1, 2026 – Devonian Health Group Inc., a clinical-stage biopharmaceutical company focused on developing therapies for fibro-inflammatory diseases, has announced significant advancements in the quality control of its lead product, Thykamine™. The company has integrated validated chemical and biological quality-control technologies into the manufacturing process, enhancing the reliability and consistency of Thykamine™.
These new quality-control measures include validated High-Performance Liquid Chromatography coupled with Mass Spectrometry (HPLC-MS), Nuclear Magnetic Resonance (NMR) spectroscopy, and a cell-based biological potency assay using the U937 human cell line. The U937 cell-based assay specifically measures macrophage inflammatory protein-1 beta (MIP-1β), a marker of Thykamine™'s anti-inflammatory activity. Both the HPLC-MS and U937 cell-based assays have been independently validated by U.S.-based Chromak Research Inc. and Pacific BioLabs, respectively.
Dr. André Boulet, President and CEO of Devonian Health Group, emphasized the importance of these developments: "This approach is particularly relevant to botanical drug development because the FDA recognizes that chemical characterization of complex botanical products may need to be complemented by biological testing to ensure product quality and therapeutic consistency. The integration of these validated technologies directly into our quality-controlled extraction process represents a significant step in the maturation of Thykamine™ as a pharmaceutical product."
The HPLC-MS method provides a chemical fingerprint of Thykamine™, while the NMR spectroscopy offers an orthogonal analytical tool to assess overall chemical reproducibility. To date, NMR analyses have demonstrated greater than 98% reproducibility from batch to batch, further supporting the high degree of chemical consistency achieved across independently manufactured Thykamine™ batches.
"These complementary technologies provide a multi-layered framework for assessing batch consistency, combining chemical fingerprinting, orthogonal structural characterization, and biological potency testing," Dr. Boulet added. "This will help ensure that Thykamine™ is produced according to defined and reproducible chemical and biological quality standards, which is crucial as the product advances through clinical development."
The integration of these validated technologies is part of Devonian's broader strategy to build a pharmaceutical-grade botanical drug platform. The company's manufacturing process combines controlled sourcing of botanical raw materials, standardized extraction conditions, analytical characterization, biological potency testing, and pharmaceutical quality systems.
Dr. Boulet concluded, "We believe these developments represent an important advancement in the pharmaceutical development and manufacturing control of Thykamine™, which should help pave the way toward regulatory and commercial acceptance."
About Thykamine™ Thykamine™, the first product developed from Devonian's SUPREX™ platform, is a highly innovative anti-inflammatory, antioxidant, immunomodulatory, and anti-fibrotic botanical extract. Its properties have been demonstrated in numerous in vitro and in vivo studies, as well as in clinical trials for conditions such as ulcerative colitis, atopic dermatitis, psoriasis, and rheumatoid arthritis.
About Devonian Health Group Inc. Founded in 2015, Devonian Health Group Inc. is headquartered in Quebec, Canada, and operates a state-of-the-art extraction facility. The company's stock is traded on the TSXV (TSXV: GSD) and quoted on the OTCQB Venture Market (OTCQB: DVHGF).